Abstracts tagged "DMARDs"

Abstract Number: 2643 • 2016 ACR/ARHP Annual Meeting
Risk Factors of Pneumocystis Jiroveci Pneumonia (PJP) in Patients with RA and Sulfasalazine As a Possible Protective Agent
Shinji Motojima¹, Tamao Nakashita², Akira Jibatake¹, Akira Yoshida¹ and Yoshiki Yamamoto¹, ¹Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan, ²Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa-city, Japan
Background/Purpose: Pneumocystis jiroveci pneumonia (PJP) is a serious complication during the treatment in patients with variety of rheumatic disease. Postmarketing surveillance of infliximab and etnercept…
Abstract Number: 701 • 2016 ACR/ARHP Annual Meeting
In Patients with Ankylosing Spondylitis Treated with Adalimumab, Combination Therapy with DMARD, Increase the Serum Level of Adalimumab and Decrease Immunogenicity
José Rosas¹, Francisca Llinares-Tello², José Miguel Senabre-Gallego¹, Mariana Marco-Mingot³, Ana Pons¹, Xavier Barber⁴, Gregorio Santos-Soler¹, Esteban Salas-Heredia¹, Catalina Cano¹, Juan Molina³, Marina Sanchís⁴, Mario García-Carrasco⁵ and AIRE-MB Group, ¹Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ²Laboratory, Hospital Marina Baixa, Villajoyosa, Spain, ³Laboratory, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ⁴CIO, Universidad Miguel Hernández, Elche, Spain, ⁵Systemic Autoimmune Diseases Research Unit, HGR 36-CIBIOR Instituto Mexicano del Seguro Social, Puebla, Mexico
Background/Purpose: In patients with rheumatoid arthritis, methotrexate (MTX), improves the clinical efficacy of anti-TNF (TNFi), among other reasons, for reducing the immunogenicity. However, there are…
Abstract Number: 2081 • 2016 ACR/ARHP Annual Meeting
Dermal Temperature Is an Excelent Prognostic Indicator to Guide RA Therapy
JoAnn Ball¹ and Maria Greenwald², ¹rheumatology, Desert Medical Advances, Palm Deseret, CA, ²Rheumatology, Desert Medical Advances, Palm Desert, CA
Background/Purpose: Nurses and rheumatology extenders can rapidly identify rheumatoid arthritis (RA) patients who flare, with high predictive value for which individual is at high risk…
Abstract Number: 2646 • 2016 ACR/ARHP Annual Meeting
Risk of Hepatitis B Reactivation in Inflammatory Arthritis Patients Receiving Disease Modifying Anti-Rheumatic Drugs (DMARDs): A Systematic Review and Meta-Analysis
Tzu-Chieh Lin¹, Mirhelen Mendes De Abreu², Sara K. Tedeschi¹, Kazuki Yoshida³ and Daniel H. Solomon², ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Department of Epidemiology, Harvard School of Public Health, Boston, MA
Background/Purpose: There is limited information for the rate of hepatitis B reactivation in inflammatory arthritis patients. We conducted a systematic review and meta-analysis, assessing hepatitis…
Abstract Number: 709 • 2016 ACR/ARHP Annual Meeting
Development of a Novel Medication Adherence Prediction Model for Patients with Ankylosing Spondylitis Based on Results from a Global Clinical Study
Philip J Mease¹, Josef S. Smolen², Dafna D Gladman³, Joachim Sieper⁴, John Weinman⁵, Julia Sommer⁶, Pascal Nurwakagari⁷ and Maja Hojnik⁸, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Medical University of Vienna, Vienna, Austria, ³University of Toronto, Toronto, ON, Canada, ⁴Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵King's College, London, United Kingdom, ⁶GKM Gesellschaft für Therapieforschung mbH, Munich, Germany, ⁷AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁸AbbVie, Ljubljana, Slovenia
Background/Purpose: Adherence to systemic therapies, such as tumor necrosis factor inhibitors (TNFi’s), is affected by various factors and may be critical for optimal disease outcomes…
Abstract Number: 2227 • 2016 ACR/ARHP Annual Meeting
Sustained Remission and Relapse Rate after Non-Conventional DMARD Withdrawal in Patients with Rheumatoid Arthritis
Andrea Ramirez-Gomez¹, Aldo Barajas-Ochoa¹, Jose Juan Castaneda-Sanchez¹, Jose Dionisio Castillo-Ortiz¹, Jorge M. Sanchez-Gonzalez² and Cesar Ramos-Remus², ¹Unidad de Investigacion en Enfermedades Cronico-Degenerativas, Guadalajara, Mexico, ²Vicerrectoria Academica, Universidad Autonoma de Guadalajara, Guadalajara, Mexico
Background/Purpose: The treatment of rheumatoid arthritis (RA) has evolved continuously. The introduction of non-conventional DMARDs, which include biologic and targeted synthetic DMARDs (tsDMARDs), has been…
Abstract Number: 3150 • 2016 ACR/ARHP Annual Meeting
The Initial Dose of Methotrexate per Weight Is Determinant of Disease Activity and Early DAS28 Remission in DMARD-Naive Early Rheumatoid Arthritis Patients Receiving Usual Care
Tuomas Rannio¹, Juha Asikainen², Pekka Hannonen², Timo Yli-Kerttula³, Päivi Ekman⁴, Laura Kuusalo⁵, Laura Pirilä⁶, Markku Mali⁷, Marja Puurtinen-Vilkki⁷, Satu Kortelainen⁷, Johanna Paltta⁶, Kirsi Taimen⁷, Markku J. Kauppi⁸, Kari Laiho⁹, Satu Nyrhinen⁹, Heidi Mäkinen¹⁰, Pia Isomäki¹⁰, Terhi Uotila¹⁰, Kalle Aaltonen¹¹, Hannu Kautiainen¹² and Tuulikki Sokka-Isler¹, ¹Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ²Jyvaskyla Central Hospital, Jyväskylä, Finland, ³Sairaalantie 3, Satakunta Central Hospital, Rauma, Finland, ⁴Satakunta Central Hospital, Rauma, Finland, ⁵Rheumatology, Turku University Central Hospital, Turku, Finland, ⁶Turku University Hospital, Turku, Finland, ⁷Turku University Central Hospital, Turku, Finland, ⁸Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ⁹Päijät-Häme Central Hospital, Lahti, Finland, ¹⁰Tampere University Hospital, Tampere, Finland, ¹¹Helsinki University, Helsinki, Finland, ¹²Unit of Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Background/Purpose: Methotrexate (MTX) is considered as the anchor disease modifying antirheumatic drug (DMARD) in treatment of rheumatoid arthritis (RA). However, there is no advice…
Abstract Number: 1200 • 2016 ACR/ARHP Annual Meeting
Transcriptional Profiling of Early RA Synovial Tissue Reveals the Impact of Triple DMARD Treatment on T Cell Activation Pathways
Alice M Walsh¹, Sunil Nagpal¹, Mihir D Wechalekar², Yanxia Guo¹, Xuefeng Yin¹, Helen Weedon², Susanna Proudman³ and Malcolm D. Smith², ¹Immunology, Janssen Research & Development, Spring House, PA, ²Flinders University, Adelaide, Australia, ³University of Adelaide, Adelaide, Australia
Background/Purpose: While several transcriptional profiling studies of synovial biopsies have been reported from RA patients with advanced disease, there is relatively little data available from…
Abstract Number: 2238 • 2016 ACR/ARHP Annual Meeting
RA Medication Preferences Among U.S. Patients in an Online Rheumatoid Arthritis Community
Baojin Zhu¹, Lawrence Chang¹, Leilei Qian¹, Cynthia J Larmore¹, Yoko Tanaka² and Andre B. Araujo¹, ¹Eli Lilly and Company, Indianapolis, IN, ²Eli Lilly and Company, Indianapolis, KS
Background/Purpose: Medications used to manage RA vary in efficacy, safety, and convenience of use. A better understanding of patient preferences of these attributes is key…
Abstract Number: 1350 • 2016 ACR/ARHP Annual Meeting
Asymptomatic Coccidioidomycosis in Patients with Rheumatic Disease: 8 Years of Experience
Usman Ajaz¹, Jeffrey R. Lisse², Neil M. Ampel³ and Dominick Sudano⁴, ¹Department of Medicine, University of Arizona, Tucson, AZ, ²Arizona Arthritis Center, University of Arizona, Tucson, AZ, ³Department of Infectious Disease, Southern AZ VA Medical Center, Tucson, AZ, ⁴Department of Rheumatology, University of Arizona, Tucson, AZ
Background/Purpose: Coccidioidomycosis (valley fever) is an endemic fungal infection that typically causes a self-limited pulmonary illness in the Southwestern United States,. Immunosuppressed patients are at…
Abstract Number: 2460 • 2016 ACR/ARHP Annual Meeting
Predictive Factors of Good Response to Conventional Dmards in Patients with Early Seronegative Rheumatoid Arthritis: Data from the Espoir Cohort
JULIA MARY¹, B Combe², Cédric Lukas³ and Michel De Bandt⁴, ¹RHEUMATOLOGY, CHU Fort de France, 97261, Martinique, ²Immuno-Rhumatologie, CHU Lapeyronie, University of Montpellier, France, ³Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁴Rheumatology department, CHU Fort de France, Fort de France, France
Background/Purpose: Early seronegative rheumatoid arthritis (RA) is a separate entity. Less is known about its initial clinical presentation and outcome due to the difficulty in…
Abstract Number: 1439 • 2016 ACR/ARHP Annual Meeting
The EP4 Receptor Antagonist CR6086 Is More Effective Than Classical NSAID and DMARD Treatment in a Murine Model of Arthritis and in Human RA Synovial Explants
Marije I. Koenders¹, Monique M. Helsen¹, Birgitte Walgreen¹, Wim B. van den Berg¹, Gianfranco Caselli², Ornella Letari² and Peter M. van der Kraan¹, ¹Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ²Rottapharm Biotech, Monza, Italy
Background/Purpose: CR6086 is a novel small molecule acting as a potent and selective antagonist of the prostaglandin E2 (PGE2) receptor EP4 subtype (EP4 receptor). Recent…
Abstract Number: 2469 • 2016 ACR/ARHP Annual Meeting
How Rheumatoid Arthritis Patients and Rheumatologists Communicate during Clinic Visits When a New DMARD Is Prescribed
Lorie L. Geryk¹, Susan J. Blalock², Courtney A. Roberts², Beth L. Jonas³ and Delesha M. Carpenter⁴, ¹Division of Pharmaceutical Outcomes and Policy, University of North Carolina, Chapel Hill, NC, ²Division of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, ³Thurston Arthritis Research Ct, University of North Carolina Thruston Arthritis Research Center, Chapel Hill, NC, ⁴Division of Pharmaceutical Outcomes and Policy, University of North Carolina, Asheville, NC
Background/Purpose: This observational study includes data from clinic visits of 38 RA patients (3 rheumatologists) that occurred in a southeastern state from May 2014 to…
Abstract Number: 1587 • 2016 ACR/ARHP Annual Meeting
A Phase 2a, 4-Week Double-Blind, Proof-of-Concept Efficacy and Safety Study of CC-292 Versus Placebo As Co-Therapy with Methotrexate in Active Rheumatoid Arthritis (RA)
Alan J Kivitz¹, Ramesh Gupta², Guillermo Valenzuela³, Edwin Smith⁴, Quaiser Rehman⁵, Hisham El Kadi⁶, Elizabeth Bretton⁷, Jacob A. Aelion⁸, Anurekh Chadha⁹, John Tesser¹⁰, Douglas Hough¹¹, Shimon Korish¹², Peter H. Schafer¹³, Garth Ringheim¹⁴, Donna Sutherland¹⁵ and Li LI¹⁶, ¹Altoona Arthritis & Osteo Ctr, Duncansville, PA, ²Private Practice, Memphis, TN, ³Integral Rheumatology & Immunology Specialists, Fort Lauderdale, FL, ⁴Rheumatology, Medical University of South Carolina, Charleston, SC, ⁵Rheumatology Clinic of Houston, Houston, TX, ⁶Arthritis & Osteoporosis Associates, Freehold, NJ, ⁷Albuquerque Clinical Trials, Albuquerque, NM, ⁸West Tennessee Research Institute, Jackson, TN, ⁹Department of Rheumatology, Austin Regional Clinic, Austin, TX, ¹⁰Arizona Arthritis and Rheumatology Research, PLLC, Pheonix, AZ, ¹¹Clinical Research, Celgene Corporation, Warren, NJ, ¹²33 Technology Drive, Celgene Corporation, Warren, NJ, ¹³Department of Translational Development, Celgene Corporation, Summit, NJ, ¹⁴Translational Medicine, Celgene Corporation, Summit, NJ, ¹⁵Clinical Research, Celgene Corporation, Summit, NJ, ¹⁶Biostatistics, Celgene Corporation, Summit, NJ
Methods: 47 adult female RA subjects were randomized 1:1 CC-292 375 mg PO daily or placebo (PBO). Subjects were required to have a diagnosis of…
Abstract Number: 2477 • 2016 ACR/ARHP Annual Meeting
Short Term Clinical Response to Initial Treatment with High Versus Low Dose Methotrexate in Mono- and Combination Therapy in Early Rheumatoid Arthritis Patients
SA Bergstra¹, CF Allaart¹, R van den Berg¹, A Chopra², N Govind³, MJ Santos⁴, TWJ Huizinga⁵ and RBM Landewé^6,7, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ²Department of Rheumatology, Center for Rheumatic Diseases, Pune, India, Pune, India, ³Department of Rheumatology, University of the Witwatersrand, Johannesburg, South Africa, Johannesburg, South Africa, ⁴Rheumatology, Department of Rheumatology, Hospital Garcia de Orta, Almada, Portugal, Almada, Portugal, ⁵Leiden University Medical Centre, Leiden, Netherlands, ⁶Amsterdam Rheumatology & Immunology Center, Netherlands, Amsterdam, Netherlands, ⁷Zuyderland Medical Center, Heerlen, Netherlands, Heerlen, Netherlands
Background/Purpose: Aiming at rapid decrease of disease activity, there has been a trend to start with higher doses of methotrexate (MTX) for newly diagnosed rheumatoid…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].